| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:CP5V
CAS:2509359-75-3
Package:10mg，100mg，500mg，1g，2g，5g，10g，More
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:CP5V
CAS:2509359-75-3
Purity:95% Package:1mg;5mg;10mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:CP5V
CAS:2509359-75-3
Package:1mg/RMB 3480;5mg/RMB 7560;10mg/RMB 9870
|
INDEX NAME NOT YET ASSIGNED manufacturers
- CP5V
-
- $393.00 / 1mg
-
2024-10-24
- CAS:2509359-75-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | INDEX NAME NOT YET ASSIGNED Basic information |
| Product Name: | INDEX NAME NOT YET ASSIGNED | | Synonyms: | CP5V;3-(1-{[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}-3,6,9,12,15-pentaoxaoctadecan-18-amido)propyl N-{2,2,2-trichloro-1-[(pyrimidin-2-yl)amino]ethyl}carbamate | | CAS: | 2509359-75-3 | | MF: | C46H66Cl3N9O12S | | MW: | 1075.5 | | EINECS: | | | Product Categories: | | | Mol File: | 2509359-75-3.mol |  |
| | INDEX NAME NOT YET ASSIGNED Chemical Properties |
| density | 1.326±0.06 g/cm3(Predicted) | | solubility | DMSO : 150 mg/mL (139.47 mM; Need ultrasonic) | | pka | 9.83±0.46(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | INDEX NAME NOT YET ASSIGNED Usage And Synthesis |
| Biological Activity | CP5V is a PROTAC, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation[1].
CP5V comprises a Cdc20 ligand and VHL binding moiety bridged by a PEG5 linker that induces Cdc20 degradation. CP5V induces degradation of Cdc20 leading to significant inhibition of breast cancer cell proliferation and resensitization of Taxol-resistant cell lines[1].CP5V profoundly degrades Cdc20 in both MCF7 and MDA-MB-231 cells with DC50 being approximately 1.6 μM[1]. | | References | [1]. Chi JJ, et al. A novel strategy to block mitotic progression for targeted therapy. EBioMedicine. 2019 Oct 25. pii: S2352-3964(19)30677-2. |
| | INDEX NAME NOT YET ASSIGNED Preparation Products And Raw materials |
|